{"entity":{"id":"georgina-long","kind":"person","name":"Georgina V. Long","aka":[],"tldr":"Melanoma trialist who led COMBI-d, COMBI-AD and NADINA, moving immunotherapy before surgery for stage III disease.","summary":"Georgina Long (Melanoma Institute Australia) led COMBI-d and COMBI-AD, the trials establishing dabrafenib plus trametinib in metastatic and adjuvant BRAF-mutant melanoma, and co-led NADINA, which showed neoadjuvant nivolumab plus ipilimumab beats adjuvant nivolumab in stage III melanoma and is changing the sequence of surgery and immunotherapy. She also led the ABC trial of immunotherapy for melanoma brain metastases and was 2024 Australian of the Year with Richard Scolyer.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Georgina_Long","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Long%20GV%5BAuthor%5D%20melanoma"}],"tags":["melanoma","neoadjuvant","australia"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":["checkpoint-inhibitor","kinase-inhibitors"],"targets":["braf","pd1","ctla4"],"drugs":["nivolumab","ipilimumab"],"companies":[],"institutions":["melanoma-institute-australia"],"pathways":[],"terms":[],"trials":["combi-ad","nadina"],"people":[],"bottlenecks":[],"keyPapers":["paper-nadina-nejm-2024"],"journals":[],"dependsOn":[],"notes":[],"role":"Co-Medical Director, Melanoma Institute Australia; Chair of Melanoma Medical Oncology and Translational Research, University of Sydney","institutionId":"melanoma-institute-australia","specialisms":["Melanoma","Neoadjuvant immunotherapy","BRAF/MEK targeted therapy","Brain metastases"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Long%20GV%5BAuthor%5D%20melanoma"}],"papers":[{"title":"Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma (NADINA)","journal":"NEJM","year":2024,"doi":"10.1056/NEJMoa2402604"},{"title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma (COMBI-AD)","journal":"NEJM","year":2017,"doi":"10.1056/NEJMoa1708539"},{"title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma (COMBI-d)","journal":"NEJM","year":2014,"doi":"10.1056/NEJMoa1406037"}],"orcid":"0000-0001-8894-3545"},"route":"/people/georgina-long/","neighbours":{"cancer":[{"id":"braf-v600-melanoma","kind":"cancer","name":"BRAF V600-mutant melanoma","route":"/cancers/braf-v600-melanoma/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"stage-iii-melanoma","kind":"cancer","name":"Stage III melanoma (after surgery)","route":"/cancers/stage-iii-melanoma/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"braf","kind":"target","name":"BRAF","route":"/targets/braf/"},{"id":"ctla4","kind":"target","name":"CTLA-4","route":"/targets/ctla4/"},{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"drug":[{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"institution":[{"id":"melanoma-institute-australia","kind":"institution","name":"Melanoma Institute Australia","route":"/institutions/melanoma-institute-australia/"}],"trial":[{"id":"combi-ad","kind":"trial","name":"COMBI-AD","route":"/trials/combi-ad/"},{"id":"combi-d","kind":"trial","name":"COMBI-d","route":"/trials/combi-d/"},{"id":"nadina","kind":"trial","name":"NADINA","route":"/trials/nadina/"}],"paper":[{"id":"paper-nadina-nejm-2024","kind":"paper","name":"NADINA: two doses of ipilimumab plus nivolumab before surgery beat a year of nivolumab after surgery in stage III melanoma","route":"/key-papers/paper-nadina-nejm-2024/"}]}}